Dacomitinib (PF299804) 99%Dacomitinib (PF299804) 1110813-31-4
Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
CAS: | 1110813-31-4 |
MF: | C24H25ClFN5O2 |
MW: | 469.9390032 |
Appearance: | White solid |
Assay: | 99% |
Boiling point: | 665.7±55.0 °C(Predicted) |
desnity: | 1.344 |
Uses: |
Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively. |
CAS NO:7647-15-6
CAS NO:420-37-1
CAS NO:13598-36-2
CAS NO:97416-84-7
CAS NO:15761-39-4
CAS NO:118-75-2
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View